China's oil sector breaks new ground with export of deepwater suction anchors to Brazil
The 24 suction caissons – which are capable of operating at depths of up to 2,000 metres – will be used to secure platforms at the Mero ultra-deepwater oilfield off Brazil's southeastern coastline, Chinese state broadcaster CCTV reported on Sunday.
The delivery represents a milestone for China's push to become a leading manufacturer of offshore oil and gas equipment, one of the strategic fields targeted in Beijing's
Made in China 2025 industrial strategy
The 24 units were designed, built and loaded at a deepwater base operated by the China National Offshore Oil Corp (CNOOC) in Zhuhai, Guangdong province. They are among the most advanced offshore equipment developed by a Chinese company ever to be shipped overseas, CCTV said.
CNOOC, China's largest offshore oil and gas producer, has seen its reserves surge in recent years. It recently announced the discovery of a major oilfield deep below an eastern section of the South China Sea, with proven reserves exceeding 100 million tonnes.
China and Brazil have been strengthening cooperation on energy in recent years, as the two members of the Brics bloc of emerging economies deepen ties across a slew of areas.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
15 minutes ago
- South China Morning Post
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. Advertisement The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRD-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their product portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The corporate flag of GlaxoSmithKline (GSK) next to a Chinese national flag outside a GlaxoSmithKline office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. Advertisement 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.
South China Morning Post
an hour ago
- South China Morning Post
InvestHK at 25: powering growth for global firms in Hong Kong and beyond
When InvestHK was established in July 2000, its mission was clear: attract overseas and mainland Chinese companies to establish or expand in Hong Kong, reinforcing its position as 'Asia's world city'. Twenty-five years on, that mission remains unchanged, but the tools and the scale of support have evolved significantly. Advertisement This year, both InvestHK and Hong Kong Exchanges and Clearing (HKEX) marked their silver jubilees with notable results. In 2024, InvestHK assisted a record 539 mainland Chinese and overseas companies in setting up operations in Hong Kong. Since its establishment in 2000, 145 of InvestHK's clients have listed on HKEX. Between January 2023 and June 2025, InvestHK helped more than 1,300 companies set up or expand in Hong Kong, bringing in over HK$160 billion (US$20 billion) in foreign direct investment. These companies created more than 19,000 jobs in their first year of operation, exceeding the government's 2022 Policy Address targets ahead of schedule. Hong Kong's initial public offering (IPO) market has maintained steady momentum in 2025, with HKEX recording more than 50 listings between January and mid-July, a year-on-year increase of 30 per cent. The exchange ranked first globally in IPO fundraising during the period, with more than 200 companies actively preparing for a public offering in the second half of the year. Support from InvestHK for overseas and mainland Chinese companies and institutions includes planning, setting up and expanding their operations in Hong Kong. The agency provides strategic advice on market entry, practical guidance during the establishment and launch phases, and continued support as businesses grow and scale across international markets via Hong Kong. When an IPO is on the horizon, InvestHK offers pre-listing workshops covering disclosure, environmental, social and governance (ESG), and investor-relations requirements, enabling founders to scale up without needing to shift jurisdictions, a stability that is increasingly valued in an era of geopolitical uncertainty. Advertisement Beyond projects: building ecosystems
South China Morning Post
2 hours ago
- South China Morning Post
Hong Kong stocks kick off trading on a strong note after US-EU trade deal
Hong Kong stocks started the week on a solid note after the US and the European Union (EU) agreed on a trade deal with a lower-than-expected tariff rate that could prevent the global economy from slipping into a recession. The Hang Seng Index rose 0.6 per cent to 25,533.23 at 10.07am local time, while the Hang Seng Tech Index dropped 0.1 per cent. On the mainland, the CSI 300 Index and the Shanghai Composite Index both climbed 0.2 per cent. China Life Insurance rallied 5.9 per cent to HK$24.10 and New Oriental Education & Technology rallied 3.9 per cent to HK$37.30. Ping An Insurance Group added 2.6 per cent to HK$56.10. The framework trade deal between the US and the EU included a 15 per cent tariff on European goods entering the US and significant EU purchases of American energy and military equipment, according to President Donald Trump. The US also struck a trade agreement with Japan last week, which triggered a rally in global equities amid fading fears of a trade war. Traders were gearing up for an eventful week: a third round of trade talks between China and the US are underway in Sweden. In addition, the US Federal Reserve will unveil its decision on interest rates and bellwether companies including HSBC Holdings are due to release first-half earnings reports.
